We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

AstraZeneca Submits sNDAs for Seroquel XR™ for the Treatment of Bipolar Mania and Bipolar Depression

News   Jan 03, 2008

 
AstraZeneca Submits sNDAs for Seroquel XR™ for the Treatment of Bipolar Mania and Bipolar Depression
 
 
Advertisement
 

RELATED ARTICLES

Novel Strategy Generates Useful Compounds for Drug Synthesis

News

A team of scientists has designed a novel catalytic method that can generate useful chiral compounds. This new strategy could provide an effective synthetic way to design pharmaceutical products.

READ MORE

Molecules Identified That Shut Down SARS-CoV-2 Polymerase Reaction

News

Researchers have discovered a library of molecules with unique structural and chemical features, capable of inhibiting the SARS-CoV-2 polymerase.

READ MORE

Existing Drugs Could Stop SARS-CoV-2 From Hijacking Cells

News

A team has analyzed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells. The scientists have also identified seven existing drugs that could disrupt these mechanisms.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE